SYNC Syncona Limited

TIDMSYNC

RNS Number : 1926N

Syncona Limited

16 January 2019

16 January 2019

Syncona Limited ("Syncona")

Appointment of Joint Corporate Broker

Syncona is pleased to announce that it has appointed Goldman Sachs International with immediate effect as joint Corporate Broker alongside Numis Securities, who remain joint Corporate Broker.

END

Enquiries:

 
 Investor enquiries 
 Annabel Clay 
  Tel: +44 (0) 20 3981 7940 
 Goldman Sachs                Numis Securities 
 Charlie Lytle                Nathan Brown 
  Tom Hartley                  James Black 
  Lucy Clarke                  Freddie Barnfield 
  Tel: +44 (0) 207 774 1000    Tel: +44 (0) 207 260 1000 
 

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPCKPDKCBKDCDD

(END) Dow Jones Newswires

January 16, 2019 02:00 ET (07:00 GMT)

Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024

Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024